Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
more bad news
when will it end
add another $2m to the yearly losses
ms lui is not pleased
$3.8m in one quarter!!!!
what are they doing printing the labels on $1 bills?
people are just laughing by now honey
the historical losses are evident
-no intl dist deal has ever lasted past initial term
-no product has ever been profitable
-bh is a recurring billing nightmare read the reviews
-sales and marketing are 300% of costs
-failure of all past trial study references to bolster sales has led the co to cease to promote them
-flonase clarispray alerflo flocare flohale flomist fluticone furamist furaspray otrivin-c airtec maxiflo esiflo seretide seroflo flute flutibact
the list goes on and on
*im telling you that the opportunity for market penetration is over
if you want to save your $ do not put it here
10 cent stock folks...ten cents for a reason
none of innovus products have ever done well enough to recoup the marketing costs and be revenue leaders before being discontinued
if one ever does you can be sure the co will start highlighting the sales breakdown in the financials
the fact that fins never show any type of per product sales analysis much less any sales analysis at all tells the market the products are losers
In the US, pharmaceutical products are in general approved in one of three ways:
A drug never before approved by FDA for a specific condition is approved using a New Drug Application (NDA) through the 505(b)(1) pathway
A generic drug referencing an already-approved NDA is approved using an Abbreviated New Drug Application (ANDA) through the 505(j) pathway
An over-the-counter (OTC) drug is approved by referencing an existing monograph
These three pathways collectively account for most of the products on the market. There are, however, several other pathways by which a drug can obtain approval.
One of the most popular of those alternative pathways is the 505(b)(2) pathway, which is designed to allow the approval of a drug which isn't new, but differs in several meaningful aspects. As described in FDA's 1999 guidance document, Applications Covered by Section 505(b)(2), a 505(b)(2) application:
"[I]s one for which one or more of the investigations relied upon by the applicant for approval 'were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted.'"
In plain terms, the 505(b)(2) sponsor is relying upon clinical data or literature produced by other companies or entities.
But why would a company want to rely on that data? The most common reason is that the 505(b)(2) sponsor has made "changes to previously approved drugs," including its recommended dose, its formulation, its route of administration, its strength, or the drugs with which it is combined.
The 505(b)(2) pathway was created with the intent "to encourage innovation without creating duplicate work and reflects the same principle as the 505(j) application: it is wasteful and unnecessary to carry out studies to demonstrate what is already known about a drug," FDA explained in its guidance.
For example, if a company were to reformulate a drug such that it could be taken just once per day instead of three times per day, it could use the 505(b)(2) pathway to minimize the amount of original data it would need to submit in support of its new drug. Regulators could instead rely upon existing data showing that the reference drug is safe and effective, and focus on determining whether the changes made to the new drug alter its safety or efficacy.
- See more at: http://www.raps.org/Regulatory-Focus/News/2015/04/08/21933/An-Increasing-Number-of-Companies-Are-Using-a-Once-Obscure-FDA-Drug-Approval-Pathway/#sthash.M3tLUEAY.dpuf
the camargo white paper indicates phase II and III studies may not be necessary
While a 505(b)(1) may require more than a decade to reach NDA submission, the 505(b)(2) pathway requires a fraction of that time — a 505(b)(2) can be developed and reach FDA approval in as little as 30 months.
bring it on
ive read all the crap out there
bh is a recurring subscription nightmare scam
the products sell
once
then get returned
total operating expenses for first quarter
$3,835,673
dead done bankrupt
heading for sub penny
get prs every day
varx gorx max fert puk its all the same
net margins are 14% gawd awful!
$12m in losses is a lock for 2017 me thinks $14.4m is likely
q2 loss $3.2m 6 straight qs of increased losses
$33.5m shareholder deficit imo
12.5 revs
14.4 loss
so what?
$45m shareholder deficit
50m shares sitting at .15
game over
too late to slowly turn bearish
net margins are 14% terrible
innovus failure
your welcome great post thanks for taking the bait!
a very sound analysis
i would add imo that nemus is best positioned to sell candidates if they wish to do so
again $20m in vc confidence says something
i also like trpx vbio and kaltf in the space but nmus is a fav for long term potential
even though my shares here are .56 avg lol
imlff will need to raise more cash and likely suffer through serious dilution and an r/s to even get to clinical testing
nmus is at the toxicoligy and ind phase and ready for p1 trials and just got $20m in cash
ind submission will be major catalyst
yes imlff is(was) a good trade nmus a better investment
imo
what happened to regia xylarid liquadd androferti xinx zytopic circumserum coraz apeaz extendryl breeze pads vap-1 akurza and levall?
and exiting 2014 cash flow positive
that was a good one
prevonco failure
nexmed failure
nexact failure
north horizon failure
fastrack failure
novalere failure
innovus ???
youre welcome
hope they do well for u
not a lot of traffic on this board
suggest going back and reading the posts as its all there
cjarmstrong vinpat and antonchigurh have good posts
basically nmus is a biotech not an mj stock
investment vs trade
historically?
what 5 quarters and theyre calling it a yearly history?
getting too embarrassing to post on this nonsense
nice spin damaje now write that $20k check
he must have hired honey
and what did it cost to buy into that anda?
i say $1.6m for 3 months of product
and now holdings will sue for boc and their royals
huge can of worms
your q1 is important q2 will be the tell all prediction is getting better all the time
chucked the last of them
not going to be left holding these twice
made a few extra grovers on the double dip pops
and the digx is gone!
does anyone know what this means?
A. Names of officers, directors and control persons:
Leonid Chernyakhovsky 30,000,000 (Preferred) 83.33%
18208 Preston Rd. Suite D9365
Dallas, TX 75252
had a bagful of 3 gift shares from over a year ago
got 11 for them and came back in at 6
can have them all at 9
a gamblers move because you know its coming
watch that finra page!
rrrrraaaaaalllllllllpppppppphhhhhhhh!
excuse me had to puke
hasnt worked for almost a year now
just a waste of money it cost at least $15k for the news posts and 8k
pr the event when the application is approved and it constitutes one
save the corp updates for tidbits in the q filings
seriously they say right in the pr that it takes 6 months for approval
enough of the promo damaje use a little fiscal prudence and stop pumping future events that rarely even amount to anything
go ahead and run the dynamic excel version and post it
and stop taking other peoples posts and rewording them into your own nonsense
damajes loc is neutral and he is no longer deferring salary
doesnt mean im in bed with him
but i know where he sleeps
it goes to show how even the most straight talking mj co deals behind the scenes
nmus does not participate in the sector game in any way
with the amount of pct ip activity it is obvious they are shopping the product heavily
u of m is not using nmus to build an in house pharma firm
they will capitalize and return to founders and shs
glad i got the .25s i did
a comparison of the last 2 quarterly cos
illustrates the huge impact the derivatives have on operations as a result of valuations
the additional 25m will likely result in another (0.02) for q2 but continued improvement in the bal sheet could be close to -1
see what this hikma deal costs and if damaje lessens the promo spending spree
if co takes extreme measures to cut costs may still reach profit this year
selling the 75m and doing r/s is as apparent as pigeon poop on the shoe though
08:30 AM NMUS Nemus Bioscience Reports Prodrug of Tetrahydrocannabinol (THC) Issued Patent Coverage in Canada and Hong Kong
good times
Dear xxx,
1) we encountered significantly higher debt to interest ratios from our express convertible fixed asset instruments compounded by lower than expected offsets to the fair value adjustment of the time decay on high yield amortized derivatives
2) we expect to be updating the progress of our guidance initiatives to more clearly indicate the scope of possible revenue goals
3) please refer to the latest quarterly report as submitted to the Securities and Exchange Commission (SEC)on form 10-k dated May 15, 2017
4) Yes well ummm HEY LOOK A BUTTERFLY!
*zing*
nice post
worth more than the last 1000 pump posts
no nobody making any trade coin here lol
can you link to your past 2 post on this board
prolly well worth a second read
youre full of it
you got 40k @ .32
and no powder @ .07
is this todays singalong?
my jukebox changes tunes less often
31m+ in losses?
im optimistic they can reach that goal yes
ill be long gone
maybe find a co run by dr profitt
you think i care?
are we at 15 yet?
im ready for lunch
what be gettin jiggy widit?
dont be down wit gansta style smak tok
k?
bro bra?
must be nobody to caddie for today
no there is no word
blatantly misleading falsifications
damaje has to go to india personally and find out why glenmark got a 5th 6 month resubmission letter due to the shut down plant
anyone can post smack
word!
tried to run figures through my finance class equations
everywhere it wants gross they list net
and vise versa
teach would call that dubious accounting practices
in that spooky voice that always made us laugh
down 15% on 600k
oh brother
cant argue with that
zestra glide vissele ejecct delay
still cant achieve penetration
go figure
have fun
ill stay and sell as many shares as i can
promise to do my best
CANT guarantee anything
remember the payed off notes?
woo hoo!
10k says
As a result of the completion of a public equity offering in March 2017 (see Note 7), we were required to prepay the outstanding principal and accrued interest balance of the 2016 Notes with the cash proceeds received from such offering
spin that penalty as positive damaje!
robbing peter to pay paul
Cash paid for interest $66,719
non-cash investing and financing activities $838,119
this is for a quarter
3 months
folks
they say they closed the offering but do not disclose the buyer
red flag
so now there is a guaranteed 15m overhead if the pps can even get back to .15
then its back to watching the paid promo prs and warrants hitting premarket and the pps heading south back to .15
hope gorx and varx do better than max
good luck to you